STAT3 and idiopathic pulmonary fibrosis: Taken together, these data demonstrate that nintedanib has a senolytic effect in vivo as well, which also implies that nintedanib, as a senolytic, is an effective drug for IPF treatment via modulating STAT3 pathway.